FDA QUALITY-BY-DESIGN PILOT PROGRAMS
This article was originally published in The Gold Sheet
Executive Summary
...for new and generic drugs are demonstrating the progress and the remaining challenges in building a stronger QbD foundation for the CMC review process. With one application cleared and several more under review in the NDA pilot, experience is now growing on how to shape a QbD-based filing from which more regulatory flexibility can flow. How detailed the QbD information should be and how to design a regulatory agreement that will clarify the ongoing commitments are among the issues generating discussion as the NDA pilot proceeds. The Office of Generic Drugs is also digesting the initial positive experience with its question-based review initiative integrating QbD principles into the ANDA review process. [An update on the NDA CMC pilot program by Office of New Drug Quality Assessment official Chi-wan Chen at the DIA annual meeting in late June and summaries by industry participants of their firms’ experience with the NDA and ANDA initiatives are included.]
You may also be interested in...
Why ‘Established Conditions’ CMC Approach Could Generate More Supporting Information, Not Less
The ‘established conditions’ concept enshrined in the ICH Q12 draft guideline was the US FDA’s answer to the background information that has cluttered new drug applications in the quality-by-design era. But early indications are that it will amass information clutter of its own.
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.